InNexus Biotechnology CEO to Present at the 7th Annual BIO Investor Forum
BRITISH COLUMBIA, Canada, Oct. 28 /PRNewswire-FirstCall/ — InNexus Biotechnology Inc., (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com/), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announces that Jeff Morhet, CEO and Chairman, will present at the 7th Annual BIO Investor Forum on October 30, 2008.
Mr. Morhet’s thirty-minute presentation to potential investors and industry partners will begin at 3:15PM within the Twin Peaks South Room of the Palace Hotel in San Francisco, California. He will provide a company overview, including information about InNexus’ unique business strategy, its DXL(TM) technology platform, recent partnerships and company milestones.
The 7th Annual BIO Investor Forum will be held October 29-31, 2008 at the Palace Hotel in San Francisco, California. The BIO Investor Forum is held every year to bring late-stage private and emerging public biotech companies and investors together to meet and attend roundtables, panel discussions and seminars on a variety of biotechnology topics.
InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit http://www.ixsbio.com/.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company’s control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.
InNexus Biotechnology Inc.
CONTACT: Wade Brooksby, Chief Financial Officer of InNexus BiotechnologyInc., +1-480-862-7500
Web site: http://www.ixsbio.com/